Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Ascendis Pharma A/S $ASND

Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,997 shares of the biotechnology company’s stock, valued at approximately $639,000.

Several other large investors have also recently modified their holdings of ASND. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $26,000. Leonteq Securities AG bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $36,000. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares during the last quarter. Global Retirement Partners LLC boosted its stake in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares during the period. Finally, Quadrant Capital Group LLC purchased a new stake in shares of Ascendis Pharma A/S during the third quarter valued at $74,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ASND shares. Morgan Stanley reissued an “overweight” rating and set a $256.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, February 12th. Wolfe Research reissued an “outperform” rating and set a $260.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Oppenheimer lifted their target price on Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $295.39.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $218.84 on Friday. The company has a market capitalization of $13.65 billion, a PE ratio of 25.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The company has a 50-day simple moving average of $233.36 and a two-hundred day simple moving average of $223.69. Ascendis Pharma A/S has a one year low of $160.86 and a one year high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. Research analysts expect that Ascendis Pharma A/S will post 12.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the transaction, the director directly owned 400 shares of the company’s stock, valued at $95,120. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.